The Chloroquine for Influenza Prevention Trial (CHIP)

National University Health System (NUHS)

Status and phase: Unknown; Phase 2

Conditions: Influenza

Treatments: Drug: Placebo; Drug: Chloroquine

Study type: Interventional

Funder types: Other

Identifiers

NCT01078779

E/09/482

Details and patient eligibility

About

A randomised controlled trial to determine the efficacy of chloroquine for the prevention of influenza

Enrollment: 1,516 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18 -65
• Have the ability to provide informed consent
• If a woman of child-bearing potential, willing to use contraception for the period of the trial

Exclusion criteria

• Acute influenza-like illness at screening
• History of psoriasis, porphyria cutanea tarda, epilepsy, myasthenia gravis, myopathy of any cause, cardiac arrhythmias, or serious hepatic or renal disease
• Pregnancy or breast feeding
• Current use of medication with known serious hepatotoxic effects
• Current use of medication with known serious interaction with CQ: amiodarone, anticonvulsants, ciclosporin, digoxin, mefloquine, moxifloxacin
• Current severe depression (as indicated by current use of antidepressant medication)
• Known serious retinal disease
• Current or recent (within the past 30 days) participation in any other clinical intervention trial.
• Known G6PD deficiency
• Vaccination for influenza (seasonal or H1N1 strain) within the 3 months prior to screening

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1,516 participants in 2 patient groups, including a placebo group

Chloroquine

Experimental group

Treatment:

Drug: Chloroquine

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo